Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Hodgkin Disease 12Lymphoma 10Testicular Neoplasms 2Teratoma 2Endodermal Sinus Tumor 2Testicular Germ Cell Tumor 1Sertoli-Leydig Cell Tumor 1Recurrence 1Ovarian gynandroblastoma 1Ovarian Germ Cell Cancer 1Lymphoma, Follicular 1HIV Infections 1Granulosa cell tumor of the ovary 1Gliosarcoma 1Glioblastoma 1Central Nervous System Neoplasms 1Carcinoma, Embryonal 1Breast Neoplasms 1

Interventions

Rituximab 131Cyclophosphamide 74fludarabine phosphate 51Whole-Body Irradiation 38Peripheral Blood Stem Cell Transplantation 36Mycophenolic Acid 36Tacrolimus 32Etoposide 28Busulfan 28Melphalan 24Lenalidomide 23Prednisone 22Filgrastim 22Cyclosporine 22Bortezomib 22Antilymphocyte Serum 21Vincristine 19Methotrexate 19obinutuzumab 17Bendamustine Hydrochloride 16fludarabine 15Doxorubicin 15Radiotherapy 14ibrutinib 13Dexamethasone 13Cytarabine 13Cord Blood Stem Cell Transplantation 13Carmustine 13pembrolizumab 12idelalisib 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Lymphoma, Follicular × Bleomycin × Clear all
NCT00577993 2020-11-16

Fludarabine, Mitoxantrone, and Dexamethasone (FND) Plus Rituximab for Lymphoma Patients

M.D. Anderson Cancer Center

Phase 3 Completed
210 enrolled 14 charts
Lymphoid

Lymphoma, Lymphoma, Follicular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡